The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

At the height of the COVID-19 pandemic, when the world was still racing to develop a vaccine, one of the key parts of the puzzle was the ability of lipid nanoparticles (LNPs) to deliver mRNA vaccines.

Every time a shuttle docks with the International Space Station (ISS), a precise and intricate process takes place between ...

Lipid nanoparticles (LNPs) represent a highly promising nonviral delivery platform ... This formulation has been successfully employed in the FDA-approved siRNA therapy, Onpattro, and has been ...

To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

The mRNA vaccine against avian influenza presents several advantages and disadvantages: Advantages: Rapid Development and Production; Non-Infectious Nature; Strong Immune Response; Adaptability to ...

Researchers have found a new way to reduce the effects of pre-eclampsia using mRNA-lipid nanoparticle therapies.